Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + carboplatin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy regimen consisting of apatinib (a VEGFR-2 inhibitor), carboplatin (a platinum-based chemotherapy agent), and pemetrexed (a folate analog). This regimen is primarily used for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). The combination works through multiple mechanisms: apatinib inhibits tumor angiogenesis, pemetrexed disrupts folate metabolism and DNA synthesis, and carboplatin forms DNA adducts that prevent replication.
02
Targets
DNADHFR (Dihydrofolate reductase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on apatinib + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + carboplatin + pemetrexed.